Page 1

Don't eat me ASPEN - 01 : A Phase 1 study of ALX148 , a CD47 blocker , in combination with trastuzumab , ramucirumab , and paclitaxel in patients with 2nd line HER2 - positive advanced gastric or gastroesophageal cancer Conference Call July 06 , 2021